Skip to main content
Erschienen in: Familial Cancer 2/2009

01.06.2009

SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women

verfasst von: Shimrit Cohen, Yael Laitman, Bella Kaufman, Roni Milgrom, Uri Nir, Eitan Friedman

Erschienen in: Familial Cancer | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Mutations in currently known genes account for only a subset of breast/ovarian cancer risk families. Three loci (2p, 4q, 22q) seemingly harbor breast cancer susceptibility genes. To explore their putative role in Jewish women, 46 affected women representing 22 high risk families were genotyped with D2S2211, D4S392, D22S278 and D22S283 and two flanking markers for each locus, and mutational analysis of ID2 (Chromosome 2) and SULT1E1 (Chromosome 4) genes was carried out in seemingly linked families. No ID2 gene mutations were detected in 8 women from the 4 families seemingly linked to D2S2211, whereas a missense mutation (His224Gln) in one affected woman from a single family was detected among 9 women from the 4 families linked to D4S392. This mutation was not found among 153 high risk, 98 sporadic breast/ovarian cancer patients, or 97 healthy controls. The SULT1E1 gene may need to be further explored as candidate breast cancer gene.
Literatur
1.
Zurück zum Zitat Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48:232–242PubMed Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48:232–242PubMed
2.
Zurück zum Zitat Forbes JF (1997) The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 24:S1–S20, S1–S35 Forbes JF (1997) The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 24:S1–S20, S1–S35
6.
Zurück zum Zitat Rohlfs EM, Learning WG, Friedman KJ et al (1997) Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43:24–29PubMed Rohlfs EM, Learning WG, Friedman KJ et al (1997) Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43:24–29PubMed
7.
Zurück zum Zitat Theodor L, Bar-Sade R, Kruglikova A et al (1998) An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews. Br J Cancer 77:1880–1883PubMed Theodor L, Bar-Sade R, Kruglikova A et al (1998) An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews. Br J Cancer 77:1880–1883PubMed
13.
Zurück zum Zitat Stacey SN, Manolescu A, Sulem P et al (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40:703–706. doi:10.1038/ng.131 PubMedCrossRef Stacey SN, Manolescu A, Sulem P et al (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40:703–706. doi:10.​1038/​ng.​131 PubMedCrossRef
14.
Zurück zum Zitat Stacey SN, Manolescu A, Sulem P et al (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39:865–869. doi:10.1038/ng2064 PubMedCrossRef Stacey SN, Manolescu A, Sulem P et al (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39:865–869. doi:10.​1038/​ng2064 PubMedCrossRef
16.
Zurück zum Zitat Benetkiewicz M, Piotrowski A, Díaz De Ståhl T et al (2006) Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity. Int J Oncol 29:935–945PubMed Benetkiewicz M, Piotrowski A, Díaz De Ståhl T et al (2006) Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity. Int J Oncol 29:935–945PubMed
17.
Zurück zum Zitat Allione F, Eisinger F, Parc P et al (1998) Loss of heterozygosity at loci from chromosome arm 22Q in human sporadic breast carcinomas. Int J Cancer 75:181–186. doi:10.1002/(SICI)1097-0215(19980119)75:2<181::AID-IJC3>3.0.CO;2-QPubMedCrossRef Allione F, Eisinger F, Parc P et al (1998) Loss of heterozygosity at loci from chromosome arm 22Q in human sporadic breast carcinomas. Int J Cancer 75:181–186. doi:10.1002/(SICI)1097-0215(19980119)75:2<181::AID-IJC3>3.0.CO;2-QPubMedCrossRef
20.
Zurück zum Zitat Raftogianis RB, Wood TC, Otterness DM et al (1997) Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298–304. doi:10.1006/bbrc.1997.7466 PubMedCrossRef Raftogianis RB, Wood TC, Otterness DM et al (1997) Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298–304. doi:10.​1006/​bbrc.​1997.​7466 PubMedCrossRef
21.
Zurück zum Zitat Raftogianis RB, Wood TC, Weinshilboum RM (1999) Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties and human liver genotype–phenotype correlations. Biochem Pharmacol 58:605–610. doi:10.1016/S0006-2952(99)00145-8 PubMedCrossRef Raftogianis RB, Wood TC, Weinshilboum RM (1999) Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties and human liver genotype–phenotype correlations. Biochem Pharmacol 58:605–610. doi:10.​1016/​S0006-2952(99)00145-8 PubMedCrossRef
26.
Zurück zum Zitat Falany JL, Falany CN (1996) Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res 56:1551–1555PubMed Falany JL, Falany CN (1996) Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res 56:1551–1555PubMed
27.
Zurück zum Zitat Suzuki T, Nakata T, Miki Y et al (2003) Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 63:2762–2770PubMed Suzuki T, Nakata T, Miki Y et al (2003) Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 63:2762–2770PubMed
28.
Metadaten
Titel
SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women
verfasst von
Shimrit Cohen
Yael Laitman
Bella Kaufman
Roni Milgrom
Uri Nir
Eitan Friedman
Publikationsdatum
01.06.2009
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2009
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-008-9218-4

Weitere Artikel der Ausgabe 2/2009

Familial Cancer 2/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.